Several challenges across Bristol Myers Squibb’s business have Leerink Partners analysts worried about the future—despite a ...

Even through an onslaught of biosimilar launches that began early last year, AbbVie’s big-selling Humira has been able to ...

Now a study from the University of Oxford indicates that the company’s semaglutide type 2 diabetes drug Ozempic can reduce ...

With a new production line up and running at its latest facility in the greater Boston area, family-owned German CDMO ...

Even as pharma companies have yet to feel the full effects of the Inflation Reduction Act, Senate lawmakers have turned their ...

After a break for the Fourth of July holiday in the U.S., we're back with two weeks' worth of biopharma news from Asia.

Pharmaceutical CEOs often earn pay packages worth tens of millions of dollars for leading the top drugmaking companies in the ...

The two companies’ applications for China-approved PD-1 inhibitor camrelizumab and the VEGFR tyrosine kinase inhibitor ...

AbbVie is asking the U.S. Supreme Court to overrule a lower court’s ruling that the company must turn over records of ...

Freshly equipped with two approved meds from Acorda Therapeutics, Frankfurt, Germany’s Merz Therapeutics is kicking its ...

Following this month's FDA approval of Eli Lilly’s amyloid-busting antibody Kisunla (donanemab), the Alzheimer’s disease ...

The dog days of summer might be in full swing, but for flu vaccine makers, its a busy time prepping for this fall's influenza ...